Chun Y S, Vauthey J N
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Unit 444, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S52-8. doi: 10.1016/j.ejso.2007.09.026. Epub 2007 Nov 19.
To review the advances in the past decade that have enabled more patients with colorectal liver metastases (CRLM) to undergo curative hepatic resection.
A comprehensive literature review and pertinent data published on advanced CRLM from The University of Texas M. D. Anderson Cancer Center were used for this review.
Criteria for resectability of CRLM have expanded with the advent of effective chemotherapy, improved surgical technique, and novel strategies such as preoperative volumetry, portal vein embolization, and two-stage hepatectomy. Despite the aggressiveness of these approaches to treating patients with advanced disease, recent series show an improvement in 5-year survival rate for patients with CRLM.
Advances in multidisciplinary management and careful patient selection have enabled more patients to undergo curative resection for CRLM, with corresponding improvement in survival rates.
回顾过去十年取得的进展，这些进展使更多结直肠癌肝转移（CRLM）患者能够接受根治性肝切除术。
本综述使用了全面的文献回顾以及德克萨斯大学MD安德森癌症中心发表的关于晚期CRLM的相关数据。
随着有效化疗的出现、手术技术的改进以及术前容积测量、门静脉栓塞和分期肝切除术等新策略的应用，CRLM的可切除标准已经扩大。尽管这些治疗晚期疾病患者的方法具有侵袭性，但最近的系列研究显示CRLM患者的5年生存率有所提高。
多学科管理的进展和谨慎的患者选择使更多患者能够接受CRLM的根治性切除，生存率相应提高。
